ALN-HSD-NASH-2130
Brief description of study
The goal of study 1 and study 2 is to evaluate the effects of ALN-HSD on liver fibrosis and other histologic features of NASH in participants with NASH and F2/F3 fibrosis and risk alleles for HSD17B13. Necessary screening procedures include blood tests, liver stiffness measurement, study-specific genotype criteria, and a liver biopsy. If eligible, subjects will receive drug at site administered by site staff for 52 weeks.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
